MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$30,526K
EPS
-$0.43
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-04-30
2026-01-31
2025-10-31
2025-07-31
Research and development
22,195
22,255
26,755*
22,575
General and administrative
9,773
8,930
6,569*
7,372
Total operating expenses
31,968
31,185
33,324
29,947
Loss from operations
-31,968
-31,185
-33,324*
-29,947
Interest income
2,663
2,740
2,727*
2,233
Interest expense
745
732
720*
758
Loss on extinguishment of debt
-
-488
0*
-
Other expenses, net
-177
-87
271*
-280
Total other income, net
1,741
1,433
2,278*
1,195
Net loss before income taxes
-30,227
-29,752
-31,046*
-28,752
Provision for income taxes
0
0
-717*
239
Net loss
-30,227
-29,752
-30,329*
-28,991
Unrealized loss (gain) on available-for-sale investments
-299
46
1,251*
-240
Total comprehensive loss
-30,526
-29,706
-29,078
-29,231
Basic EPS
-0.43
0.44
-0.569
0.57
Diluted EPS
-0.43
0.44
-0.569
0.57
Basic Average Shares
69,724,761
67,263,234
51,141,247
51,097,711
Diluted Average Shares
69,724,761
67,263,234
51,141,247
51,097,711
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Total comprehensive
loss
-$30,526K
Net loss
-$30,227K
Unrealized loss (gain) on
available-for-sale investments
-$299K
Interest income
$2,663K
Net loss before
income taxes
-$30,227K
Total other income,
net
$1,741K
Interest expense
$745K
Other expenses, net
-$177K
Loss from operations
-$31,968K
Total operating
expenses
$31,968K
Research and development
$22,195K
General and
administrative
$9,773K
Buy us a coffee
enGene Therapeutics Inc. (ENGN)
enGene Therapeutics Inc. (ENGN)